NasdaqCM - Delayed Quote USD

Bellevue Life Sciences Acquisition Corp. (BLAC)

Compare
11.40
+0.06
+(0.53%)
As of January 3 at 4:00:00 PM EST. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
Operating Expense
2,242.35
1,830.70
35.39
3.31
Operating Income
-2,242.35
-1,830.70
-35.39
-3.31
Net Non Operating Interest Income Expense
2,144.30
2,775.29
--
--
Pretax Income
-98.06
944.59
-35.39
-3.31
Tax Provision
376.80
540.81
--
--
Net Income Common Stockholders
-474.86
403.78
-35.39
-3.31
Diluted NI Available to Com Stockholders
-474.86
403.78
-35.39
-3.31
Basic EPS
-0.09
0.05
-0.00
-0.00
Diluted EPS
-0.09
0.05
-0.00
-0.00
Basic Average Shares
5,502.69
7,688.26
9,055.00
7,930.00
Diluted Average Shares
5,502.69
7,719.70
9,055.00
7,930.00
Total Operating Income as Reported
-2,242.35
-1,830.70
-35.39
--
Total Expenses
2,242.35
1,830.70
35.39
3.31
Net Income from Continuing & Discontinued Operation
-474.86
403.78
-35.39
-3.31
Normalized Income
-474.86
403.78
-35.39
-3.31
Interest Income
2,144.30
2,775.29
--
--
Net Interest Income
2,144.30
2,775.29
--
--
EBIT
-2,242.35
-1,830.70
-35.39
-3.31
EBITDA
-2,242.35
-1,830.70
-35.39
-3.31
Net Income from Continuing Operation Net Minority Interest
-474.86
403.78
-35.39
-3.31
Normalized EBITDA
-2,242.35
-1,830.70
-35.39
-3.31
Tax Rate for Calcs
0.00
0.00
--
--
12/31/2021 - 3/21/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers